

# Multidrug-resistant Gram-negative (MDRGN) Infection - Pipeline Insight, 2020

<https://marketpublishers.com/r/M6E5828BA843EN.html>

Date: February 2020

Pages: 106

Price: US\$ 2,000.00 (Single User License)

ID: M6E5828BA843EN

## Abstracts

This report can be delivered to the clients within 48-72 Hours

Multidrug-resistant Gram-negative (MDRGN) Infection Overview

'Multidrug-resistant Gram-negative (MDRGN) Infection Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Multidrug-resistant Gram-negative (MDRGN) Infection Market. A Detailed Picture Of The Multidrug-resistant Gram-negative (MDRGN) Infection Pipeline Landscape Is Provided, Which Includes The Disease Overview And Multidrug-resistant Gram-negative (MDRGN) Infection Treatment Guidelines.

The Assessment Part Of The Report Embraces In-Depth Multidrug-resistant Gram-negative (MDRGN) Infection Commercial Assessment And Clinical Assessment Of The Multidrug-resistant Gram-negative (MDRGN) Infection Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.

In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Multidrug-resistant Gram-negative (MDRGN) Infection Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.

Multidrug-resistant Gram-negative (MDRGN) Infection Of Pipeline Development Activities

The Report Provides Insights Into:

All Of The Companies That Are Developing Therapies For The Treatment Of Multidrug-resistant Gram-negative (MDRGN) Infection With Aggregate Therapies Developed By Each Company For The Same.

Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The Multidrug-resistant Gram-negative (MDRGN) Infection Treatment.

Multidrug-resistant Gram-negative (MDRGN) Infection Key Players Involved In Targeted Therapeutics Development With Respective Active And Inactive (Dormant Or Discontinued) Projects.

Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.

Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of Multidrug-resistant Gram-negative (MDRGN) Infection Market.

The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.

Multidrug-resistant Gram-negative (MDRGN) Infection Analytical Perspective By DelveInsight

In-Depth Multidrug-resistant Gram-negative (MDRGN) Infection Commercial Assessment Of Products

This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And

Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.

Multidrug-resistant Gram-negative (MDRGN) Infection Clinical Assessment Of Products

The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.

## **SCOPE OF THE REPORT**

The Multidrug-resistant Gram-negative (MDRGN) Infection Report Provides An Overview Of Therapeutic Pipeline Activity And Therapeutic Assessment Of The Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type For Multidrug-resistant Gram-negative (MDRGN) Infection Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.

It Comprises Of Detailed Profiles Of Multidrug-resistant Gram-negative (MDRGN) Infection Therapeutic Products With Key Coverage Of Developmental Activities, Including Technology, Collaborations, Licensing, Mergers And Acquisition, Funding, Designations And Other Product-Related Details

Detailed Multidrug-resistant Gram-negative (MDRGN) Infection Research And Development Progress And Trial Details, Results Wherever Available, Are Also Included In The Pipeline Study.

Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across Multidrug-resistant Gram-negative (MDRGN) Infection.

## **REPORT HIGHLIGHTS**

A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For Multidrug-resistant Gram-negative (MDRGN) Infection.

In The Coming Years, The Multidrug-resistant Gram-negative (MDRGN) Infection Market Is Set To Change Due To The Rising Awareness Of The Disease, And Incremental Healthcare Spending Across The World; Which Would Expand The Size Of The Market To Enable The Drug Manufacturers To Penetrate More Into The Market.

The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence Multidrug-resistant Gram-negative (MDRGN) Infection R&D. The Therapies Under Development Are Focused On Novel Approaches To Treat/Improve The Disease Condition.

A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The Multidrug-resistant Gram-negative (MDRGN) Infection Treatment Market. Several Potential Therapies For Multidrug-resistant Gram-negative (MDRGN) Infection Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Multidrug-resistant Gram-negative (MDRGN) Infection Market Size In The Coming Years.

Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of Multidrug-resistant Gram-negative (MDRGN) Infection ) Includes Therapeutic Assessment And Comparative Analysis. This Will Support The Clients In The Decision-Making Process Regarding Their Therapeutic Portfolio By Identifying The Overall Scenario Of The Research And Development Activities.

## KEY QUESTIONS

What Are The Current Options For Multidrug-resistant Gram-negative (MDRGN) Infection Treatment?

How Many Companies Are Developing Therapies For The Treatment Of Multidrug-resistant Gram-negative (MDRGN) Infection?

What Are The Principal Therapies Developed By These Companies In The Industry?

How Many Therapies Are Developed By Each Company For The Treatment Of

Multidrug-resistant Gram-negative (MDRGN) Infection?

How Many Multidrug-resistant Gram-negative (MDRGN) Infection Emerging Therapies Are In Early-Stage, Mid-Stage, And Late Stage Of Development For The Treatment Of Multidrug-resistant Gram-negative (MDRGN) Infection?

Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?

What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact Multidrug-resistant Gram-negative (MDRGN) Infection Market?

Which Are The Dormant And Discontinued Products And The Reasons For The Same?

What Is The Unmet Need For Current Therapies For The Treatment Of Multidrug-resistant Gram-negative (MDRGN) Infection?

What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing Multidrug-resistant Gram-negative (MDRGN) Infection Therapies?

What Are The Clinical Studies Going On For Multidrug-resistant Gram-negative (MDRGN) Infection And Their Status?

What Are The Results Of The Clinical Studies And Their Safety And Efficacy?

What Are The Key Designations That Have Been Granted For The Emerging Therapies For Multidrug-resistant Gram-negative (MDRGN) Infection?

How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of Multidrug-resistant Gram-negative (MDRGN) Infection?

## Contents

### **1. REPORT INTRODUCTION**

### **2. MULTIDRUG-RESISTANT GRAM-NEGATIVE (MDRGN) INFECTION**

#### 2.1. Overview

#### 2.2. History

#### 2.3. Multidrug-resistant Gram-negative (MDRGN) Infection Symptoms

#### 2.4. Causes

#### 2.5. Pathophysiology

#### 2.6. Multidrug-resistant Gram-negative (MDRGN) Infection Diagnosis

##### 2.6.1. Diagnostic Guidelines

### **3. MULTIDRUG-RESISTANT GRAM-NEGATIVE (MDRGN) INFECTION CURRENT TREATMENT PATTERNS**

#### 3.1. Multidrug-resistant Gram-negative (MDRGN) Infection Treatment Guidelines

### **4. MULTIDRUG-RESISTANT GRAM-NEGATIVE (MDRGN) INFECTION - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE**

#### 4.1. In-depth Commercial Assessment

##### 4.1.1. Multidrug-resistant Gram-negative (MDRGN) Infection companies collaborations, Licensing, Acquisition -Deal Value Trends

###### 4.1.1.1. Assessment Summary

##### 4.1.2. Multidrug-resistant Gram-negative (MDRGN) Infection Collaboration Deals

###### 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

###### 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

###### 4.1.2.3. Multidrug-resistant Gram-negative (MDRGN) Infection Acquisition Analysis

### **5. THERAPEUTIC ASSESSMENT**

#### 5.1. Clinical Assessment of Pipeline Drugs

##### 5.1.1. Assessment by Phase of Development

##### 5.1.2. Assessment by Product Type (Mono / Combination)

###### 5.1.2.1. Assessment by Stage and Product Type

##### 5.1.3. Assessment by Route of Administration

###### 5.1.3.1. Assessment by Stage and Route of Administration

- 5.1.4. Assessment by Molecule Type
  - 5.1.4.1. Assessment by Stage and Molecule Type
- 5.1.5. Assessment by MOA
  - 5.1.5.1. Assessment by Stage and MOA
- 5.1.6. Assessment by Target
  - 5.1.6.1. Assessment by Stage and Target

## **6. MULTIDRUG-RESISTANT GRAM-NEGATIVE (MDRGN) INFECTION LATE STAGE PRODUCTS (PHASE-III)**

## **7. MULTIDRUG-RESISTANT GRAM-NEGATIVE (MDRGN) INFECTION MID STAGE PRODUCTS (PHASE-II)**

## **8. EARLY STAGE PRODUCTS (PHASE-I)**

## **9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS**

## **10. INACTIVE PRODUCTS**

## **11. DORMANT PRODUCTS**

## **12. MULTIDRUG-RESISTANT GRAM-NEGATIVE (MDRGN) INFECTION DISCONTINUED PRODUCTS**

## **13. MULTIDRUG-RESISTANT GRAM-NEGATIVE (MDRGN) INFECTION PRODUCT PROFILES**

- 13.1. Drug Name: Company
  - 13.1.1. Product Description
    - 13.1.1.1. Product Overview
    - 13.1.1.2. Mechanism of action
  - 13.1.2. Research and Development
    - 13.1.2.1. Clinical Studies
  - 13.1.3. Product Development Activities
    - 13.1.3.1. Collaboration
    - 13.1.3.2. Agreements
    - 13.1.3.3. Acquisition
    - 13.1.3.4. Patent Detail
  - 13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table  
Detailed information in the report?

## **14. MULTIDRUG-RESISTANT GRAM-NEGATIVE (MDRGN) INFECTION KEY COMPANIES**

## **15. MULTIDRUG-RESISTANT GRAM-NEGATIVE (MDRGN) INFECTION KEY PRODUCTS**

## **16. DORMANT AND DISCONTINUED PRODUCTS**

### 16.1. Dormant Products

16.1.1. Reasons for being dormant

### 16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

## **17. MULTIDRUG-RESISTANT GRAM-NEGATIVE (MDRGN) INFECTION UNMET NEEDS**

## **18. MULTIDRUG-RESISTANT GRAM-NEGATIVE (MDRGN) INFECTION FUTURE PERSPECTIVES**

## **19. MULTIDRUG-RESISTANT GRAM-NEGATIVE (MDRGN) INFECTION ANALYST REVIEW**

## **20. APPENDIX**

## **21. REPORT METHODOLOGY**

21.1. Secondary Research

21.2. Expert Panel Validation



## List Of Tables

### LIST OF TABLES

Table 1: Multidrug-resistant Gram-negative (MDRGN) Infection Diagnostic Guidelines

Table 2: Multidrug-resistant Gram-negative (MDRGN) Infection Treatment Guidelines

Table 3: Assessment Summary

Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis

Table 5: Multidrug-resistant Gram-negative (MDRGN) Infection Acquisition Analysis

Table 6: Assessment by Phase of Development

Table 7: Assessment by Product Type (Mono / Combination)

Table 8: Assessment by Stage and Product Type

Table 9: Assessment by Route of Administration

Table 10: Assessment by Stage and Route of Administration

Table 11: Assessment by Molecule Type

Table 12: Assessment by Stage and Molecule Type

Table 13: Assessment by MOA

Table 14: Assessment by Stage and MOA

Table 15: Assessment by Target

Table 16: Assessment by Stage and Target

Table 17: Multidrug-resistant Gram-negative (MDRGN) Infection Late Stage Products (Phase-III)

Table 18: Multidrug-resistant Gram-negative (MDRGN) Infection Mid Stage Products (Phase-II)

Table 19: Multidrug-resistant Gram-negative (MDRGN) Infection Early Stage Products (Phase-I)

Table 20: Pre-clinical and Discovery Stage Products

Table 21: Inactive Products

Table 22: Dormant Products

Table 23: Discontinued Products

## List Of Figures

### LIST OF FIGURES

Figure 1: Disease Overview

Figure 2: History

Figure 3: Symptoms

Figure 4: Causes

Figure 5: Pathophysiology

Figure 6: Diagnostic Guidelines

Figure 7: Treatment Guidelines

Figure 8: Multidrug-resistant Gram-negative (MDRGN) Infection companies collaborations, Licensing, Acquisition -Deal Value Trends

Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis

Figure 10: Multidrug-resistant Gram-negative (MDRGN) Infection Acquisition Analysis

Figure 11: Assessment by Phase of Development

Figure 12: Assessment by Product Type (Mono / Combination)

Figure 13: Assessment by Stage and Product Type

Figure 14: Assessment by Route of Administration

Figure 15: Assessment by Stage and Route of Administration

Figure 16: Assessment by Molecule Type

Figure 17: Assessment by Stage and Molecule Type

Figure 18: Assessment by MOA

Figure 19: Assessment by Stage and MOA

Figure 20: Late Stage Products (Phase-III)

Figure 21: Mid Stage Products (Phase-II)

Figure 22: Early Stage Products (Phase-I)

Figure 23: Pre-clinical and Discovery Stage Products

Figure 24: Inactive Products

Figure 25: Dormant Products

Figure 26: Discontinued Products

Figure 27: Unmet Needs

## I would like to order

Product name: Multidrug-resistant Gram-negative (MDRGN) Infection - Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/M6E5828BA843EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M6E5828BA843EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970